Developing alternative routes of immunotherapies with innovative drugs for neurodegenerative and gastrointestinal diseases.

Learn more about Tiziana   Tiziana Investor Deck   Scientific Presentations and Updates

In the Media

Tiziana Life Sciences Announces Purchase of Common Shares by Chief Medical Officer

29 September 2022

New York, September 29, 2022 – Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company enabling breakthrough immunotherapies via novel routes of drug delivery, today announces that it has been notified that Matthew Davis, its Chief...

Read more

Tiziana Life Sciences Announces Presentations on Intranasal Foralumab at the “Preserving the Brain” Scientific Conference and Exhibit at the Fondazione Prada in Milan

28 September 2022

  • Effect of nasal anti-CD3 (foralumab) in animal model of Progressive Multiple Sclerosis (MS)” poster exhibit
  • Effect of nasal anti-CD3 (foralumab) in healthy subjects” poster exhibit
  • Effect of nasal anti-CD3 (foralumab) in patient with Progressive MS” poster exhibit
  • Howard L. Weiner, M.D. of Brigham...
Read more

Tiziana Life Sciences Announces Purchase of Common Shares by Chief Medical Officer

23 September 2022

New York, September 23, 2022 – Tiziana Life Sciences Ltd.(Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company enabling breakthrough immunotherapies via novel routes of drug delivery, today announces that it has been notified that Matthew Davis, its Chief Medical...

Read more

Our Mission

Our mission is to bring breakthrough therapies to patients with the aim of treating SPMS, Crohn's Disease, lung diseases and optimizing health outcomes.

Learn more

Clinical Candidates

Our major clinical assets are supported by extensive worldwide issued patents and pending patent applications covering composition of matter, formulation technologies, manufacturing processes and disease indications.

Pipeline

Foralumab

Foralumab is a fully human anti-CD3 monoclonal antibody (mAb) for treatment of Crohn’ s Disease and neurodegenerative indications.

Learn more about Foralumab

Anti IL-6 Receptor mAb
(IL-6R:TZLS-501)

We are developing a fully human monoclonal antibody (mAb) targeting the receptor for IL-6 as a potential treatment for lung diseases.

Learn more about Anti IL-6R

Milciclib

Milciclib is the Company’s Phase 2 clinical candidate for the treatment in cancer indications. The company is exploring the combination of milciclib and gemcitibine in NSCLC patients with pan KRAS+ mutations.

Learn more about Milciclib

Clinical Trials

Tiziana is currently conducting clinical development programs for Foralumab, Anti IL-6R and Milciclib

Foralumab

Tiziana reported positive clinical data in a Phase I clinical trial of nasally-dosed Foralumab in healthy subjects in collaboration with Dr. Howard Weiner at Brigham and Women’s Hospital in Boston. Phase 1 patient enrollment is expected to begin in 3Q 2022 for orally administered Foralumab for the treatment of Crohn's disease. Phase 2 patient enrollment is expected to begin in 3Q 2022 for nasally administered Foralumab for the treatment of Pro-MS.

See more Foralumab clinical trials

Anti IL-6R mAb (TZLS-501)

Manufacturing of clinical supplies for a Phase 1 study is anticipated to be completed in 3Q/4Q 2022. We anticipate filing a Australian TGA in 1Q 2023.

Milciclib

We are exploring a study to evaluate the combination of milciclib and gemcitabine in NSCLC subjects with associated pan KRAS-positive mutations. We expect to file an IND in 3Q 2022.

See more Milciclib clinical trials

Tiziana Life Sciences is listed on NASDAQ